Biotech News

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

Greenwich LifeSciences (GLSI)Greenwich LifeSciences2026-06-01 12:15 ESTClinical readout

GLSI (GLSI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is glsi.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

IMCRImmunocore Holdings plc2026-11-06 17:00 EST

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

BMYBMYBristol-Myers Squibb Company2026-10-23 14:30 EST

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026

BMYBMYBristol-Myers Squibb Company2026-11-06 21:00 EST

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

IMCRImmunocore Holdings plc2026-10-29 13:00 EST

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

GSKGSK plc2026-10-23 23:00 EST

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

RVMDRevolution Medicines2026-10-23 11:30 EST

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

GSKGSK plc2026-10-18 19:36 EST

GSK presents first global data for Ris-Rez in extensive-stage small cell lung cancer

View all latest news

Greenwich LifeSciences

Greenwich LifeSciences is an immunotherapy company focused on cancer vaccines and breast-cancer treatment. Its story is built around a narrow but potentially differentiated oncology program.

Recent company news

GLSIGreenwich LifeSciences2026-08-10 10:00 EST

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

GLSIGreenwich LifeSciences2026-07-22 10:00 EST

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

GLSIGreenwich LifeSciences2026-07-20 10:00 EST

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

GLSIGreenwich LifeSciences2026-07-16 11:30 EST

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

GLSIGreenwich LifeSciences2026-07-09 10:00 EST

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Stock data

Close: 14.65 USD
Market cap: 356.53M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States